HEPALINK(09989) Stock Price Today | Quotes & News

HK Stock MarketDetailed Quotes

09989 HEPALINK

Watchlist

4.440
+0.040+0.91%

Not Open Apr 24 16:08 CST

6.51BMarket Cap9.27P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Earnings Preview: HEPALINK to Report Financial Results on April 25
Moomoo News19:45 ET
Highpree: First quarter report 2025
SZSI12:00 ET · Announcements
Shenzhen Hepalink's Ivenoxin Gains Approval for South African Market
TipRanksApr 24 06:39 ET
HEPALINK (09989): Ivenoxin received market approval from the South African Health Products Regulatory Authority.
HEPALINK (09989) announced that its wholly-owned subsidiary Shenzhen Tiandao Pharmaceutical Co., Ltd. produces Enoxaparin Sodium...
Zhitong FinanceApr 24 06:24 ET
HEPALINK (09989) released its first-quarter results, with a net income of 0.157 billion yuan, a year-on-year increase of 1%.
HEPALINK (09989) reported its first quarter results for 2025, with revenue of 1.394 billion yuan, a year-on-year increase of 1...
Zhitong FinanceApr 24 06:23 ET
Express News | Shenzhen Hepalink Pharmaceutical - Ivenoxin Produced by Unit Approved by South African Health Products Regulatory Authority for Sale in Market
ReutersApr 24 06:22 ET

Comments

Moomoo AI

Feb 4, 2024 10:01

Shenzhen Hepalink Pharmaceutical Group's P/E remains high despite price drop, justified by superior earnings outlook. Investors see low risk of earnings deterioration, providing strong share price support.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399) Stocks Pounded By 35% But Not Lagging Market On Growth Or Pricing

Moomoo AI

Jan 17, 2024 07:23

The market's muted reaction to the company's declining EPS and share price might be due to expectations of a business turnaround. However, the company's poor performance last year and long-term share price weakness could indicate unresolved challenges.

Investors Five-year Losses Continue as Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Dips a Further 5.9% This Week, Earnings Continue to Decline

Moomoo AI

Dec 21, 2023 20:21

Investors overlook limited growth potential of Shenzhen Hepalink, increasing risk of future disappointment if P/S ratio aligns with growth outlook. A hike in future revenue projections may justify current P/S ratio.

Unpleasant Surprises Could Be In Store For Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Shares

Moomoo AI

Dec 21, 2023 20:04

Shenzhen Hepalink's limited growth potential seems overlooked by investors buying the stock, risking future disappointment when the P/S ratio aligns with growth outlook. Analysts hope for a positive shift in future revenue forecasts to justify current price-to-sales ratio.

Unpleasant Surprises Could Be In Store For Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Shares

Moomoo AI

Dec 21, 2023 19:53

Shenzhen Hepalink's limited growth outlook is ignored by investors optimistic about its stock, creating a risky scenario if future revenue projections do not match its current price-to-sales ratio.

Unpleasant Surprises Could Be In Store For Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Shares